Be the first person to write a business review for Eurand, Inc.

Flamel Technologies S.A. was founded in 1990 and is headquartered in Venissieux, France. Flamel Technologies S.A., a biopharmaceutical company, engages in the development of polymer-based drug delivery technologies for the improvement of medical applications in France. Its Medusa nanoparticulate technology is designed to deliver therapeutic proteins, peptides, and other large and small molecules injected subcutaneously. The company's Micropump technology is a multiparticulate technology for oral administration of small molecule drugs with applications in controlled-release, taste-masking, and bioavailability enhancement. Its products based on Medusa technology include Interferon-AlphaXL, an interferon-alpha 2b for the treatment of hepatitis C virus and various oncology applications; FT-105 basal insulin, a long-acting formulation of recombinant human insulin to insulin-dependent patients; and interleukin-2 for the treatment of renal cancer. The company's products based on Micropump technology comprise Coreg CR, an extended release formulation of carvedilol phosphate for use in the treatment of moderate to severe heart failure and left ventricular dysfunction following myocardial infarction, and hypertension; and Asacard162.5mg, a controlled release formulation of aspirin, which provide therapy for cardiovascular treatment. It has strategic alliances with GlaxoSmithKline, Merck Serono, Wyeth Pharmaceuticals, Pfizer, Corning S.A., Servier, and Corning Incorporated.

Generex Biotechnology Corporation company was founded in 1983 and is based in Toronto, Canada. Generex Biotechnology Corporation, a development stage company, engages in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases. It develops a proprietary platform technology for the oral administration of large molecule drugs, including proteins, peptides, monoclonal antibodies, hormones, and vaccines. The company's products include Generex Oral-lyn, an insulin spray formulation used for the treatment of Type-1 and Type-2 diabetes; Glucose RapidSpray, which provides an alternative for people who require additional glucose in their diet, as well as delivers glucose formulation directly into the mouth; BaBOOM! Energy Spray, an instant energy spray designed to increase energy levels for sports, work, study, travel, and overall fatigue; and Crave-NX, a fat-free glucose spray that is used as an aid for dieters. Generex Biotechnology Corporation's under development products include medicinal chewing gum for the treatment of Type-2 diabetes mellitus and obesity; morphine and fentanyl products for breakthrough and postoperative pain; and AE37, an immunotherapeutic vaccine that is in Phase II clinical trials for patients with HER-2/neu positive breast cancer. The company markets its products through distributors and retail chains in Ecuador, Canada, and the United States. It has collaboration with Fertin Pharma A/S for the development of a metformin medicinal chewing gum.

Hospira, Inc. company was founded in 2003 and is headquartered in Lake Forest, Illinois. Hospira, Inc., a specialty pharmaceutical and medication delivery company, engages in the development, manufacture, and marketing of pharmaceuticals and medication delivery systems in the United States and internationally. It offers generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management systems for hospitals, wholesalers, integrated delivery networks, and alternate site providers, such as clinics, home healthcare providers, and long-term care facilities. The company primarily provides specialty injectable pharmaceutical products that consist of generic injectable pharmaceuticals for analgesia, anesthesia, anti-infective, cardiovascular, and oncology therapeutic areas, as well as Precedex (dexmedetomidine HCl), a proprietary sedative. Its proprietary drug delivery options include Carpuject and iSecure prefilled syringes, Ansyr prefilled needleless emergency syringe systems, First Choice ready-to-use premixed formulations, and the ADD-Vantage System for preparing drug solutions from prepackaged drug powders or concentrates.Hospira, Inc. company also offers infusion therapy solutions and supplies that include I.V. solutions for general use; and I.V. nutrition products and solutions for the washing and cleansing of wounds or surgical sites. In addition, it provides medication management systems that include electronic drug delivery pumps, safety software, and administration sets that are used to deliver I.V. fluids and medications. Further, the company offers gravity administration sets, hemodynamic monitoring systems used to monitor cardiac function and blood flow in critically ill patients, disposable blood-pressure-sensing devices, blood sampling systems, catheter systems, and needle stick safety products. Additionally, Hospira involves in the provision of formulation development, and injectable and oral drug filling and finishing services.

Hyaluron, Inc. company specializes in aseptically filling syinges and vials with liquid and lyophilized (treated for preservation) products serving the medical and pharmaceutical markets. Hyaluron manufacturing facility can accomodate the needs of clients small and large, from pre-clincial batches to commercial scale development. Hyaluron's expertise also extends into scaling up formulations such as emulsions, viscous gels, suspensions, liposomes, and proteins which will eventually fill the vials and syringes of the company's clients. The company can fill about 150,000 syringes a day and 75,000 vials.

InSite Vision Incorporated company was founded in 1986 and is based in Alameda, California. InSite Vision Incorporated operates as an ophthalmic product development company in the United States. It engages in the development and commercialization of ophthalmic pharmaceutical products based on DuraSite drug delivery technology. The company offers AzaSite for the treatment of bacterial conjunctivitis. It develops ISV-502, which completed Phase III (a) clinical trial for the treatment of blepharoconjunctivitis, an infection of the eyelid and the conjunctiva, as well as other ophthalmic infections; and ISV-405, a preclinical development candidate for the treatment of ocular infection. InSite Vision Incorporated has collaborative, licensing, and service agreements with Shin Poong Pharm Co., Ltd.; Bioceutica S.A.; Biem Pharmaceuticals; Essex Bio-Technology; Pfizer Inc. and Pfizer Products, Inc.; and Inspire Pharmaceuticals, Inc.; Catalent Pharma Solutions; and Bausch and Lomb Incorporated.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.